NSABP FB-10: Phase IB Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) with Neratinib in Women with Metastatic HER2-Positive Breast Cancer

Jame Abraham,¹ Shannon L. Puhalla,² William M. Sikov,³ Alberto J. Montero,¹ Jan H. Beumer,² Marc E. Buyse,⁴ Laura M. Adamson,⁵ Ashok Srinivasan,⁵ Katherine L. Pogue-Geile,⁵ Samuel A. Jacobs⁵

¹NSABP, and The Cleveland Clinic, Cleveland, OH; ²NSABP, and The University of Pittsburgh Cancer Institute, Pittsburgh, PA; ³NSABP, and The Women and Infants Hospital of Rhode Island, Providence, RI; ⁴International Drug Development Institute (IDDI), Louvain-Ia-Neuve, Belgium; ⁵NSABP, Pittsburgh, PA



Abstr CT013

Supported by Puma Biotechnology, Inc.

AACR 2017 Disclosure Information

The following authors declare the following potential conflicts of interest:


- Jame Abraham: Genentech (Speaker); Pfizer (Speaker)
- Shannon L. Puhalla: Abbvie, Pfizer, Lilly, Novartis, Incyte, Covance-Bayer, Eisai (Grant/Research support); Abbvie, Medimmune, Alldex (Consultant); Alldex (Data Monitoring Board Member)
- Marc E. Buyse: IDDI (Employee and stockholder)

All other authors declare no other potential conflicts of interest There will be no discussion of off-label use and/or investigational use in this presentation.



Trastuzumab Emtansine (T-DM1)

- T-DM1 is a conjugated antibody. Trastuzumab is armed to deliver the maytansinoid antimicrotubule agent, DM1, to antigenexpressing HER2-positive cells
- DM-1, a potent cytotoxic agent, binds to microtubules similar to vinca alkaloids




LoRusso PM, et al. *Clin Cancer Res* 2011;17:6437-47



Neratinib: Tyrosine Kinase Inhibitor

- Neratinib, an oral TKI, irreversibly inhibits pan-ERBB receptor tyrosine kinases
- Irreversible binding due to covalent interaction between neratinib and cysteine residue within ATP binding site



Mohamed A, et al. *Am J Pathol* 2013; 183:1096-12 DOI: 10.1016/j.ajpath.2013.07.005



Clinical Background

- EMILIA, a phase III randomized trial of T-DM1 v capecitabine plus lapatinib (C-L) in MBC pts previously treated in first-line with trastuzumab plus taxane
 - PFS: T-DM1 v C-L was 9.4 mo v 6.4 mo (p<0.001)</p>
 - ORR: T-DM1 v C-L was 43.6% v 30.8 % (p=0.001)
- T-DM1 after trastuzumab and pertuzumab (retrospective study) 17.9% tumor response rate
- Current preferred regimen in first-line metastatic BC
 - Pertuzumab-naïve pts: trastuzumab/pertuzumab/taxane
 - Pertuzumab-exposed pts: T-DM1
- Neratinib in phase II trial had single-agent activity in trastuzumabresistant pts
 - PFS: 5.5 mo
 - ORR: 24%

NSABJ

Verma S, et al. *NEJM* 2012; 367:1783 Krop I, et al. *Lancet Oncol* 2014; 15:689 Burstein H, et al. *J Clin Oncol* 2010; 28:1301 Dzimitrowicz H, et al. *J Clin Oncol* 2016; 34:3511

NSABP FB-10 Overview

Metastatic HER2-Positive Breast Cancer with Prior Trastuzumab and Pertuzumab Treatment

Study Entry

Treatment Regimen for All Patients T-DM1 3.6 mg/kg i.v. Day 1 every 21 days* Neratinib PO daily beginning on Day 1 of T-DM1 and continuing until disease progression

*T-DM1 Dose level 1

Dose de-escalation will proceed on the basis of dose-limiting toxicity during Cycle 1.

Neratinib Dose Escalation Levels

- Dose level 1: 120 mg/day
- Dose level 2: 160 mg/day
- Dose level 3: 200 mg/day
- Dose level 4: 240 mg/day

NSABF

Loperamide 4mg q6h initiated with first dose of neratinib

Primary Aim for Phase Ib

Aim: To determine the safety and tolerability of T-DM1 and neratinib

Endpoint: Recommended phase II dose (RP2D) of T-DM1 and neratinib that can be administered in combination



Secondary Aims

- Objective response rate (ORR)
- Progression-free survival (PFS)
- Clinical benefit rate (CR, PR, and SD)
- Toxicity
- Correlative studies



Key Eligibility

- Confirmed diagnosis of invasive adenocarcinoma of the breast
- Documentation of measurable disease
- Breast cancer determined to be HER2-positive
- Must have had anti-HER2-based therapy with trastuzumab and pertuzumab as neoadjuvant, adjuvant, or in first-line metastatic disease



Key Ineligibility

- Previous therapy with T-DM1 or any HER2 TKI
- Persistent > grade 2 diarrhea
- Symptomatic brain metastases
- Active hepatitis
- Conditions significantly affecting GI function



Patient Characteristics

Characteristic	N=22
Age Mean Range	48.3 34-67
Performance status 0 1	16 6
ER- or PR-positive Yes No	12 10
Trastuzumab + pertuzumab Neoadjuvant Adjuvant Metastatic	13 3 6
Sites of metastatic disease Brain Visceral Skin/lymph node Bone	7 14 13 9

NSABP

Dose-Limiting Toxicities (DLTs) by Dose of Neratinib


Cohort, mg/d of neratinib	No. of pts	No. of DLTs	Grade of diarrhea / dehydration (No. of pts)
120	6	1	3 (1)
160	4	0	_
200	8	3	2 (1) / 3 (1) 3 (2)
240	3	2	2 (1) / 3 (1) 3 (1)



Treatment-related Adverse Events (All doses)

	N=21							
	Adverse Event	Any Grade	Gr 1 #Pts (%)	Gr 2 #Pts (%)	Gr 3 #Pts (%)	Gr 4 #Pts (%)	Gr 5 #Pts (%)	
	Diarrhea	85%	3 (14)	11 (52)	4(19%)	0	0	
	Nausea	66%	4 (19)	7 (33)	3 (14)	0	0	
-	Anorexia	39%	2 (10)	6 (29)	0	0	0	
	Fatigue	39%	1 (5)	6 (29)	1 (5)	0	0	
	Vomiting	47%	7 (33)	3 (14)	0	0	0	
	Thrombocytopenia	49%	6 (30)	1 (5)	3 (14)	0	0	
	Neutropenia	15%	1 (5)	1 (5)	1 (5)	0	0	
	AST elevation	74%	11 (58)	2 (11)	1 (5)	0	0	
	Bilirubin elevation	20%	2 (10)	1 (5)	0	0	0	
NSABP	Hypertension	29%	1 (5)	3 (14)	2 (10)	0	0	


% Change in Size of Target Lesions



5 non-evaluable pts: Withdrew consent: 1; DLTs: 4


NSABP

Evaluable Patients by Dose-level (RECIST)



NSABP

FC-7 and FB-10: Neratinib Trough Concentration at Steady-state, Day 1 of Cycle 2



- Trough levels are overlapping at all study doses
- Need more complete PK data to correlate toxicity and response (peak concentration and AUC)




Progression in skin, contralateral breast mass, lung, and multiple liver lesions





Neratinib 120 mg



Neratinib 120 mg

NSABP

After 2 cycles of treatment

Baseline



After 1 Cycle of Treatment



After 3 Cycles of Treatment



Neratinib 160 mg



Conclusions

- Diarrhea was the major dose-limiting toxicity in this dose-escalation trial
- In patients with prior trastuzumab and pertuzumab, activity was seen across all dose-levels of neratinib
 ORR (CR/PR): 9 of 16 (56%)
- Additional patients are being accrued at 160 mg/d of neratinib to define the RP2D



Future Directions

- A Phase II trial will be conducted at the RP2D and will evaluate PK more fully to determine if any correlation with response and toxicity
- Phase II study will evaluate anti-diarrheal regimen with loperamide and budesonide, which has been shown to decrease occurrence of grade 3 diarrhea*
 - Patients experiencing diarrhea on pertuzumab appear to be at high risk for diarrhea on neratinib and may benefit from more intense anti-diarrheal management



Acknowledgements

- We thank our patients and their family members
- Our outstanding clinical trial team
- NSABP study team
- Puma Biotechnology, Inc.

